Market closed

BioMarin/$BMRN

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About BioMarin

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Ticker

$BMRN
Trading on

Industry

Biotechnology

Employees

3,040

BioMarin Metrics

BasicAdvanced
$13B
30.91
$2.21
0.33
-
$13B
0.33
$94.85
$60.63
1.6M
5.325
2.963
10.519
10.519
45.02%
5.15%
8.05%
30.914
4.549
2.3
2.5
26.745
17.97%
153.71%
15.62%
84.68%

What the Analysts think about BioMarin

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BioMarin stock.

BioMarin Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BioMarin Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BMRN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for BioMarin stock?

BioMarin (BMRN) has a market cap of $13B as of April 03, 2025.

What is the P/E ratio for BioMarin stock?

The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 30.91 as of April 03, 2025.

Does BioMarin stock pay dividends?

No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of April 03, 2025.

When is the next BioMarin dividend payment date?

BioMarin (BMRN) stock does not pay dividends to its shareholders.

What is the beta indicator for BioMarin?

BioMarin (BMRN) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.